FDA Expands Test for Gastric and Esophageal Cancers - Top-Institutions - MDSpire

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.

  • By

  • Kathryn Wighton

  • July 14, 2026

  • 2 min

Share

Top Institutions in Pathology

Brief introduction explaining scope and methodology.

  • #1

    National Cancer Institute
    National Cancer Institute

    Bethesda, MD

    Key Differentiators

    • Oncology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Oncology

  • #3

    Sidney Kimmel Comprehensive Cancer Center
    Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Oncology

  • #4

    Garden State Cancer Center
    Garden State Cancer Center

    Belleville, NJ

    Key Differentiators

    • Oncology

  • #5

    University of Pittsburgh
    University of Pittsburgh

    Pittsburgh, PA

    Key Differentiators

    • Oncology

Original Source(s)

FDA Expands Test for Gastric and Esophageal Cancers

  • by Kathryn Wighton

  • July 14, 2026

Related Content

NEJM Retracts Avacopan Vasculitis Study

"The primary end-point assessments in nine patients were readjudicated after database lock and trial unblinding"

Congo Ebola Outbreak Strains Care Delivery

“We live with fear in our stomachs"

Misdiagnosis Common in Parkinsonian Disorders

Autopsy-confirmed findings linked diagnostic errors, co-pathology, and genetic variation to distinct pathologic patterns across more than 3,300 donors with Parkinsonian disorders.